For the year ending 2025-12-31, PHAT had -$167,292K decrease in cash & cash equivalents over the period. -$167,004K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -221,247 |
| Depreciation and amortization | 633 |
| Stock-based compensation | 28,719 |
| Accrued payment-in-kind interest on debt | 4,664 |
| Accrued interest on revenue interest financing liability, net of payments | 24,333 |
| Amortization of debt discount | 3,014 |
| Inventory reserve | 280 |
| Other | -5,205 |
| Prepaid expenses and other current assets | -5,513 |
| Accounts receivable, net | 39,331 |
| Accounts payable and accrued expenses | 34,104 |
| Accrued interest | 121 |
| Operating right-of-use assets and lease liabilities | 222 |
| Inventory | 11,781 |
| Other long-term assets | 1,224 |
| Net cash used in operating activities | -166,775 |
| Cash paid for property and equipment | 229 |
| Net cash used in investing activities | -229 |
| Proceeds from issuance of common stock from exercise of stock options | 1,638 |
| Net proceeds from issuance of debt | 0 |
| Net proceeds from underwritten public offering | 0 |
| Payment of employee tax obligations related to vesting of psus and rsus | -1,926 |
| Net cash (used in) provided by financing activities | -288 |
| Net decrease in cash and cash equivalents and restricted cash | -167,292 |
| Cash and cash equivalents and restricted cash - beginning of period | 300,125 |
| Cash and cash equivalents and restricted cash - end of period | 132,833 |
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)